New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
11:18 EDTLEAP, COH, JNJOptions with increasing implied volatility: LEAP COH JNJ
News For LEAP;COH;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
09:09 EDTCOHCoach sees annual financial improvement beginning in FY16
Subscribe for More Information
09:07 EDTCOHCoach sees low double digit decline in FY15 constant currency, reported sales
Subscribe for More Information
08:59 EDTCOHCoach says still targeting China sales of over $600M in FY15
Subscribe for More Information
08:11 EDTCOHCoach report Q1 EPS ex-items 53c, consensus 45c
07:21 EDTJNJCBI to hold a conference
Subscribe for More Information
07:02 EDTCOHCoach reports Q1 EPS 43c, consensus 45c
Subscribe for More Information
October 27, 2014
15:36 EDTCOHNotable companies reporting before tomorrow's open
Subscribe for More Information
07:29 EDTJNJWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
October 24, 2014
08:15 EDTJNJJohnson & Johnson management to meet with JPMorgan
Meetings to be held in Chicago/Kansas City on October 29 hosted by JPMorgan.
06:32 EDTJNJJohnson & Johnson found 'not liable' in all-metal hip implant suit, WSJ reports
Subscribe for More Information
October 23, 2014
05:58 EDTJNJStocks with implied volatility below IV index mean; XLNX JNJ
Subscribe for More Information
October 22, 2014
17:50 EDTJNJBavarian Nordic announces expanded collaboration with Janssen on MVA-BN
Bavarian Nordic A/S announced that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to expand the collaboration announced earlier to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets. Bavarian Nordic and Janssen will collaborate on the evaluation of MVA-BN for three additional infectious disease targets. Janssen is granted the exclusive option to collaborate on one or more of the targets, following scientific evaluation of MVA-BN-based vaccine candidates, which will be developed by Bavarian Nordic.
05:31 EDTJNJJohnson & Johnson announces commitment to speed Ebola vaccine development
Subscribe for More Information
October 20, 2014
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
October 17, 2014
16:55 EDTJNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use